Who we are

Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases.

At a glance

Our company by the numbers

50,129,284

Patients with neurodegenerative diseases

42

Employees living and working across the world

58%

Improvement in memory functions for clinical trial patients

2016

Year we were officially founded

The Founders

Ed boyden
Ed Boyden

Founder

Li huei tsai
Li-Huei Tsai

Founder

Meet the team

You?

Brent Vaughan
Brent Vaughan

Chief Executive Officer

Ralph Kern
Ralph Kern

Chief Medical Officer

Mihaly Hajos
Mihály Hajós

Chief Scientific Officer

Everett Crosland
Everett Crosland

Chief Commercial Officer

Kim Kwan 2023
Kim Kwan

Chief Technology Officer

Jennifer Newberger
Jennifer Newberger

Senior Vice President, Regulatory & Compliance

Celine Houser
Celine Houser

Vice President, Clinical Operations

Kimberly ha
Kimberly Ha

PR & Investor Relations

Recognized and proud

Aetion Logo 1
DAC Logo 1 2
DIME Logo 1
Norman Felix institute
Providence HP logo 2
Latest news and updates

Stay up to date

Article placeholder black

May 9, 2023

Neuroimmune Interactions: From Basic Mechanisms to Novel Therapeutic Directions
Article placeholder black

Apr 17, 2023

Cognito finds new medical, technology heads in BrainStorm, Philips alums
Article placeholder black

Mar 23, 2023

Neuro Startup Cognito Corrals $73M as Alzheimer’s Device Commences Key Test
Article placeholder black

Mar 22, 2023

Can light reset brainwaves to treat Alzheimer’s? This Boston startup has $73 million to find out.